EICHOR About Solutions

Recruiting studies: Locally Advanced Or Metastatic Digestive Tract Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05631964 Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancre
Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT05705492 The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Phase 3 · 3 location(s) · Quercis Pharma AG · NCT06861088 A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695 Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520 AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metasta
Phase 1/Phase 2 · 18 location(s) · Avenzo Therapeutics, Inc. · NCT07038343 Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Yuhan Corporation · NCT06975410 A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Phase 2 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07450976 First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186 Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer
Phase N/A · 1 location(s) · CHA University · NCT06893380 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116 A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Phase 1 · 20 location(s) · Astellas Pharma Inc · NCT07094204 Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agen
Phase 1/Phase 2 · 7 location(s) · Novartis Pharmaceuticals · NCT07468071 Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Phase 1/Phase 2 · 19 location(s) · Yuhan Corporation · NCT05523947 Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017 A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 · 85 location(s) · Daiichi Sankyo · NCT06172478 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Phase 1/Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT06792435 A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary
Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07582315 A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metas
Phase 3 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07606599 A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Lo
Phase 1/Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06031584 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants Wi
Phase 1 · 11 location(s) · IDEAYA Biosciences · NCT07540572 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/Phase 2 · 77 location(s) · PMV Pharmaceuticals, Inc · NCT04585750 VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1/Phase 2 · 15 location(s) · VM Oncology, LLC · NCT03556228 A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771 Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Radiopharm Theranostics, Ltd · NCT07189871 Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494 A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381 A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →